United Therapeutics Corporation Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
United Therapeutics Corp. (UTHR) PT Lowered to $106 at Cowen
October 31, 2018 12:28 PM EDTCowen analyst Chris Shibutani lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $106.00 (from $110.00) while maintaining a Market Perform rating.
... MoreUnited Therapeutics (UTHR) Tops Q3 EPS by 73c, Revenues Beat
October 31, 2018 6:08 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $3.98, $0.73 better than the analyst estimate of $3.25. Revenue for the quarter came in at $412.7 million versus the consensus estimate of $380.43 million.
"We are pleased to see continued growth in the number of U.S. patients treated... More
